Vor Biopharma’s (VOR) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reiterated their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a research report released on Thursday morning,RTT News reports. Wedbush currently has a $7.00 target price on the stock.

A number of other analysts have also recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research report on Tuesday, December 10th. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Tuesday, December 10th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $10.79.

Vor Biopharma Trading Up 0.9 %

VOR opened at $0.85 on Thursday. The stock has a market cap of $58.51 million, a price-to-earnings ratio of -0.52 and a beta of -0.40. Vor Biopharma has a 1 year low of $0.63 and a 1 year high of $2.43. The stock has a fifty day moving average price of $1.23 and a 200 day moving average price of $1.01.

Hedge Funds Weigh In On Vor Biopharma

Several large investors have recently made changes to their positions in the business. Two Sigma Investments LP lifted its position in shares of Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock worth $181,000 after purchasing an additional 25,930 shares during the last quarter. Trustees of Columbia University in the City of New York acquired a new position in shares of Vor Biopharma during the 4th quarter worth about $102,000. RA Capital Management L.P. lifted its position in shares of Vor Biopharma by 74.3% during the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after purchasing an additional 16,897,159 shares during the last quarter. Northern Trust Corp lifted its position in shares of Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after purchasing an additional 44,252 shares during the last quarter. Finally, Lynx1 Capital Management LP acquired a new position in shares of Vor Biopharma during the 4th quarter worth about $707,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.